16 results
6-K
EX-99.3
PRFX
PainReform Ltd
13 May 21
PAINREFORM LTD. Condensed UNAUDITED FINANCIAL STATEMENTS
9:18am
addition to the team as we advance our clinical trials and begin preparations for commercial activities. Her skill sets and leadership skills should
20-F
2020 FY
PRFX
PainReform Ltd
18 Mar 21
Annual report (foreign)
9:03am
with special expertise and skills for limited engagements, including drug product manufacture and quality assurance.
Organizational Structure
We
424B3
PRFX
PainReform Ltd
25 Nov 20
Prospectus supplement
11:12am
leadership skills, should be invaluable as we work towards our goal of establishing PRF-110 as the standard of care in the post-operative non-opiate
6-K
EX-99.1
yqbu6e 6iyrlq
25 Nov 20
PainReform Appoints Senior Pharmaceutical Executive and Finance Veteran Ilan Hadar as Chief Executive Officer
10:08am
6-K
EX-99.1
7bul5jr
13 Nov 20
Report of Foreign Private Issuer
6:09am
424B4
fwtai
2 Sep 20
Prospectus supplement with pricing info
4:09pm
F-1/A
q7qrpvn232f ippe
31 Aug 20
Registration statement (foreign) (amended)
6:06am
F-1/A
1l8duf
24 Aug 20
Registration statement (foreign) (amended)
12:15pm
F-1/A
3cfa0fhut5a9go05
10 Aug 20
Registration statement (foreign) (amended)
4:15pm
F-1/A
kv1bpi13
5 Aug 20
Registration statement (foreign) (amended)
1:26pm
F-1
cqrsxhg hmw4
30 Jun 20
Registration statement (foreign)
5:16pm
DRS/A
t74tg1d6
2 Jun 20
Draft registration statement (amended)
12:00am
DRS/A
5mhr091dlx6uqj0k
12 May 20
Draft registration statement (amended)
12:00am
DRS
2medmi
3 Feb 20
Draft registration statement
12:00am
- Prev
- 1
- Next